Skip to main content
January 14, 2021
A phase 3 clinical trial evaluating the efficacy of extended-release injectable risperidone for patients with schizophrenia showed a statistically significant delay in time to relapse, compared to the placebo.
December 31, 2020
CME Program: Christoph U. Correll, MD and Rakesh Jain, MD, MPH discuss efficacy with LAIA treatment in schizophrenia
December 02, 2020
Treatment with a long-acting injectable antipsychotic combined with cognitive training significantly improved cognitive deficits in patients after a first episode of schizophrenia, according to a study published online in Psychological Medicine.
November 02, 2020
Janssen is seeking US Food and Drug Administration (FDA) approval for the first long-acting injectable (LAI) medication for schizophrenia that would be taken only twice a year.
September 11, 2020
Patients initiated on long-acting injectables for the treatment of schizophrenia had fewer hospitalizations and emergency department visits, compared with patients treated with oral antipsychotics, according to a poster presented at Psych Congress 2020. 
September 11, 2020
In patients with recent-onset schizophrenia, the rate of major treatment failure with longer treatment was lower with paliperidone palmitate than with oral antipsychotics, according to a poster presented at Psych Congress 2020. 
July 02, 2020
CME Program: Saundra Jain, MA, PsyD, LPC and Leslie Citrome, MD, MPH discuss LAIAs adherence in patients with schizophrenia.
Back to Top